CanSino Biologics Inc
SSE:688185

Watchlist Manager
CanSino Biologics Inc Logo
CanSino Biologics Inc
SSE:688185
Watchlist
Price: 56.64 CNY 2.46%
Market Cap: 9.2B CNY
CanSino Biologics Inc
/
Income Statement
/
Revenue

CanSino Biologics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CanSino Biologics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
CanSino Biologics Inc
SSE:688185
Revenue
¥357.1m
CAGR 3-Years
168%
CAGR 5-Years
216%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Revenue
¥12.3B
CAGR 3-Years
7%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Revenue
¥10.9B
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Revenue
¥28B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Revenue
¥40B
CAGR 3-Years
3%
CAGR 5-Years
6%
CAGR 10-Years
8%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Revenue
¥2.1B
CAGR 3-Years
16%
CAGR 5-Years
10%
CAGR 10-Years
N/A

CanSino Biologics Inc
Glance View

Market Cap
9.2B CNY
Industry
Pharmaceuticals

CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Intrinsic Value
64.11 CNY
Undervaluation 12%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is CanSino Biologics Inc's Revenue?
Revenue
357.1m CNY

Based on the financial report for Dec 31, 2023, CanSino Biologics Inc's Revenue amounts to 357.1m CNY.

What is CanSino Biologics Inc's Revenue growth rate?
Revenue CAGR 5Y
216%

Over the last year, the Revenue growth was -65%. The average annual Revenue growth rates for CanSino Biologics Inc have been 168% over the past three years , 216% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 246,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.